## AIZ: Assurant, Inc. - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 1.46 indicates fundamental undervaluation. Quality metrics strong (ROE 15%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($219.82)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Bank of Nova Scotia Acquires 47,054 Shares of Assurant, Inc. $AIZ**
- Source: MarketBeat | 20251211T084931 | Neutral | Relevance: 99%
- Bank of Nova Scotia significantly increased its stake in Assurant, Inc. (NYSE:AIZ) by 878.5% during the second quarter, purchasing an additional 47,054 shares to own a total of 52,410 shares valued at $10.35 million. This investment activity highlights institutional confidence in Assurant, with other firms also adjusting their positions in the financial services provider. Despite recent insider selling by CEO Keith Demmings, analysts maintain a "Moderate Buy" rating for Assurant, with an average price target of $250.00, suggesting continued growth potential for the company, which also recently increased its quarterly dividend.

**2. Amundi Lowers Stake in Assurant, Inc. $AIZ**
- Source: MarketBeat | 20251211T083131 | Somewhat-Bullish | Relevance: 98%
- Amundi significantly reduced its holdings in Assurant, Inc. by 74.9% during the second quarter, now owning 91,976 shares worth approximately $17.6 million. Despite Amundi's reduction, other institutional investors like Charles Schwab and UBS AM increased their stakes, bringing total institutional ownership to 92.65%. Assurant also announced an increased quarterly dividend and received a "Moderate Buy" consensus rating from analysts with an average target price of $250.00.

**3. Zacks Research Has Pessimistic View of Assurant Q1 Earnings**
- Source: MarketBeat | 20251211T114928 | Neutral | Relevance: 98%
-  Zacks Research has lowered its Q1 2026 EPS estimate for Assurant (NYSE:AIZ) to $5.15 and maintained a "Hold" rating, projecting a full-year 2026 EPS of $20.75. Despite this, most sell-side analysts have a "Moderate Buy" consensus rating and a $250 price target. Assurant has also increased its quarterly dividend to $0.88, indicating a 1.6% yield, and maintains high institutional ownership of 92.65%, although CEO Keith Demmings recently sold a portion of his shares.

**4. Federated Hermes Inc. Has $53.99 Million Stake in Assurant, Inc. $AIZ**
- Source: MarketBeat | 20251209T100816 | Somewhat-Bullish | Relevance: 98%
-  Federated Hermes Inc. has reduced its stake in Assurant, Inc. by 17.9% during the second quarter, now holding 273,391 shares valued at approximately $53.99 million. Despite this, other institutional investors have increased their positions in Assurant, and Wall Street analysts generally maintain a "Moderate Buy" rating with a consensus price target of $250.00. The company recently increased its quarterly dividend and reported solid financial performance, including a return on equity of 18.61%.

**5. Qube Research & Technologies Ltd Purchases 515,127 Shares of Assurant, Inc. $AIZ**
- Source: MarketBeat | 20251211T122535 | Somewhat-Bullish | Relevance: 98%
- Qube Research & Technologies Ltd significantly increased its stake in Assurant, Inc. (NYSE:AIZ) by 482.8% in Q2, acquiring 515,127 additional shares. This brings their total holding to 621,830 shares, valued at approximately $122.8 million. Concurrently, Assurant's CEO, Keith Demmings, sold 13,725 shares, and the company announced an increase in its quarterly dividend to $0.88 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Keefe, Bruyette | $254 | $248 | +2% |
| 2025-11-17 | Morgan Stanley | $248 | $232 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Keefe, Bruyette | main | Outperform |
| 2025-11-17 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 2 ($0.10M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 55.5% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 1 / 9 |

**Top Holders:**
- Vanguard Group Inc: 13.2% (-2.0%)
- Bank Of New York Mel: 10.0% (+23.7%)
- Blackrock Inc.: 7.9% (-0.4%)
- T. Rowe Price Invest: 7.7% (-3.5%)
- State Street Corpora: 5.4% (-3.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Balance sheet: strong liquidity (11492000000.0x). Institutional flow bearish (9 selling vs 1 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $11.5B |
| Beta | 0.57 |
| 52W Range | $174.97 - $232.02 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 11.0 |
| Current P/E | 11.7 |
| YoY Growth | 6.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -3.5% to -0.9% (+2.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.0pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.0%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.95% (CS: 39) | Neutral |
| RSI_14 | 60.7 | Neutral |
| MACD Histogram | -0.47 | Bearish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.038x | Above |
| vs SMA200 | 1.108x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $228.02
- **Stop Loss:** $219.82 (3.6% risk)
- **Target:** $244.42 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 168
- **Position Value:** $38,307.36
- **Portfolio %:** 38.31%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-10 (Est: $5.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.28 | $5.73 | +34.0% |
| 2025Q2 | $4.45 | $5.10 | +14.5% |
| 2025Q1 | $2.78 | $3.39 | +22.1% |
| 2024Q4 | $4.13 | $4.79 | +15.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*